Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People with a good general performance level, able to carry out normal daily activities with little or no limitation (confirm with trial site what this means for specific circumstances)
• People who have been diagnosed with non-small cell lung cancer confirmed through a tissue or cell sample
• People whose cancer has spread to the brain and has gotten worse after a previous first-line cancer treatment
• People whose brain metastases meet specific size and volume requirements — either measurable tumours that have not been treated with radiation, or tumours treated with a targeted form of radiotherapy that were smaller than a certain size (confirm with trial site for exact measurements)
• People who showed a positive response to a previous immunotherapy treatment (checkpoint inhibitor) at their first assessment
• People whose brain tumours, if previously treated with radiation, received a total radiation dose within safe limits for surrounding brain structures
• People with measurable brain tumours visible on MRI that are large enough to be measured accurately and repeatedly
• People who have had all areas of cancer outside the brain assessed by scan (such as CT or PET-CT) within 14 days before starting the trial
• People who have had a brain MRI scan within 14 days before starting the trial
• People whose estimated survival is greater than 12 weeks
• People of childbearing potential who agree to use effective contraception during the trial, and who have a negative pregnancy test before starting
• People who are not currently breastfeeding
• People with adequately functioning organs (as assessed by the trial site)
• People who are willing and able to give informed consent and follow all study requirements, including visits, tests, and treatment schedules

Who may not be able to join:

• People who have previously experienced severe (grade 3–4) toxic effects on the brain or pituitary gland from prior treatment
• People who do not have any measurable brain tumours that have not already been treated with radiation
• People whose cancer has spread to the lining of the brain or spinal cord (meningeal metastasis)
• People who have not completed a required waiting period after their last chemotherapy or targeted therapy (at least 3 weeks), or after brain tumour surgery (at least 2 weeks)
• People with significant autoimmune diseases
• People who have previously been treated with a type of immunotherapy called a CTLA-4 inhibitor
• People who have had another cancer in the past 5 years or who currently have another cancer
• People with a history of severe allergic reaction to any monoclonal antibody or to components of the study drug
• People with a history of, or currently having, non-infectious lung inflammation (pneumonitis) or interstitial lung disease that has required treatment with steroid medicines
• People who have had a serious infection within 4 weeks before starting the trial
• People who have a history of organ transplant or bone marrow/stem cell transplant from a donor
• People who have been taking high-dose steroid medicines or other immune-suppressing drugs within 14 days before starting the trial
• People with significant heart or cardiovascular disease
• People currently enrolled in another interventional clinical trial at the same time
• People who have received a live vaccine within 30 days before starting the trial, or who plan to receive one during the study
• People with a known history of mental illness, or substance, alcohol, or drug misuse
• People who are pregnant or breastfeeding
• People with any other medical condition, treatment history, or abnormal test result that the trial site determines could affect the study results or the person's wellbeing

Important: Always verify eligibility with the trial site directly before applying.